Acute Kidney Injury Pathology

Quick Answer

CICM Exam Focus

Key Points

---

KDIGO Definition and Classification

The KDIGO Criteria (2012)

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines established the current international consensus definition of AKI (PMID: 22890468).

KDIGO Staging

Limitations of KDIGO Criteria

1. Creatinine lag: Creatinine does not rise until 24-72 hours after injury onset, missing the therapeutic window
2. Non-steady state problems: In acute illness, creatinine kinetics are unreliable
3. Muscle mass dependency: Lower baseline creatinine in elderly, cachectic, or female patients may mask AKI
4. Volume dilution: Fluid resuscitation dilutes creatinine, underestimating injury severity
5. Pre-existing CKD: High baseline creatinine means a smaller absolute rise represents greater injury

---

Classification: Pre-renal, Intrinsic, Post-renal

Overview of AKI Categories

Pre-renal AKI

Pre-renal AKI results from decreased effective renal perfusion with structurally intact nephrons. The kidney responds appropriately with sodium and water retention.

Pathophysiology

1. Reduced cardiac output: Heart failure, cardiogenic shock, massive PE
2. Hypovolaemia: Haemorrhage, dehydration, third-spacing, burns
3. Systemic vasodilation: Sepsis (early), anaphylaxis, cirrhosis (hepatorenal syndrome)
4. Renal vasoconstriction: NSAIDs, calcineurin inhibitors, hepatorenal syndrome
5. Altered autoregulation: ACE inhibitors/ARBs in volume-depleted states

The ACE Inhibitor/ARB Mechanism

The "Triple Whammy" effect describes the combination of:

• ACE inhibitor/ARB: Efferent arteriolar vasodilation
• NSAID: Afferent arteriolar vasoconstriction (blocks protective prostaglandins)
• Diuretic: Volume depletion

This combination causes profound reduction in GFR (PMID: 23303357).

Intrinsic AKI

Intrinsic AKI involves structural damage to the nephron and is categorised by anatomical location:

Post-renal AKI

Obstruction of the urinary tract causes increased intratubular pressure, which is transmitted retrograde to Bowman's capsule, reducing the net filtration pressure.

Pathophysiology of Obstruction

1. Acute phase (0-6 hours): Increased renal blood flow due to afferent arteriolar vasodilation (prostaglandin-mediated)
2. Subacute phase (6-24 hours): Afferent arteriolar vasoconstriction due to angiotensin II, thromboxane A2
3. Chronic phase (>24 hours): Sustained reduction in RBF, tubular atrophy, interstitial fibrosis

---

Tubular Epithelial Injury: Acute Tubular Necrosis

Anatomy and Vulnerability of the S3 Segment

The proximal tubule is divided into S1, S2, and S3 segments. The S3 segment (pars recta) located in the outer stripe of the outer medulla is most vulnerable to ischaemic injury (PMID: 24434187).

Why the S3 Segment is Vulnerable

Brush Border Loss and Cellular Changes

The proximal tubule brush border amplifies the apical membrane surface area 20-40 fold for reabsorption. During ischaemia:

1. ATP depletion → Na+/K+-ATPase failure → intracellular sodium accumulation
2. Cell swelling → compression of peritubular capillaries → worsening ischaemia
3. Cytoskeletal disruption → actin depolymerisation, loss of cell polarity
4. Brush border shedding → microvilli detach into tubular lumen
5. Loss of cell-cell adhesion → cells detach from basement membrane
6. Cast formation → detached cells and debris obstruct tubular lumen

Tubular Backleak

With loss of tubular epithelial integrity, the glomerular filtrate leaks back into the interstitium and peritubular capillaries. This "backleak" means that even if GFR were normal, effective clearance is reduced because filtrate is not delivered to the collecting system.

---

Ischaemia-Reperfusion Injury

Phases of Ischaemia-Reperfusion Injury

Ischaemia-reperfusion injury (IRI) is the most common cause of ATN in hospitalised patients and occurs in four distinct phases (PMID: 24434187).

Phase 1: Initiation (The Ischaemic Insult)

ATP Depletion:

• Oxygen deprivation → cessation of oxidative phosphorylation
• ATP levels fall to 10-20% of baseline within 15-30 minutes
• Shift to anaerobic glycolysis → lactate accumulation → intracellular acidosis

Pump Failure:

• Na+/K+-ATPase failure → intracellular sodium rises
• Secondary failure of Na+/Ca2+ exchanger → intracellular calcium rises
• Cell swelling due to osmotic water entry

Cytoskeletal Disruption:

• ATP-dependent actin polymerisation ceases
• F-actin depolymerises to G-actin
• Spectrin cleaved by calcium-activated calpains
• Loss of integrin-basement membrane adhesion

Phase 2: Extension (The Reperfusion Injury)

Paradoxically, restoration of blood flow causes additional injury through:

Reactive Oxygen Species (ROS):

• Xanthine oxidase (converted from dehydrogenase during ischaemia) generates superoxide
• Mitochondrial electron transport chain dysfunction → electron leak → ROS
• NADPH oxidase activation in infiltrating neutrophils
• ROS species: superoxide (O2•-), hydrogen peroxide (H2O2), hydroxyl radical (•OH)

Mitochondrial Permeability Transition Pore (mPTP):

• Calcium overload + ROS + ATP depletion → mPTP opening
• Loss of mitochondrial membrane potential
• Release of cytochrome c → caspase activation → apoptosis
• Further ATP depletion as proton gradient dissipates

Phase 3: Maintenance

During maintenance, GFR remains at its nadir due to:

1. Tubular obstruction: Sloughed cells and casts block tubular flow
2. Tubuloglomerular feedback: Increased NaCl at macula densa → afferent vasoconstriction
3. Backleak: Filtrate leaks through damaged epithelium
4. Persistent vasoconstriction: Endothelin-1, reduced NO bioavailability
5. Ongoing inflammation: Cytokine production, leukocyte infiltration

Phase 4: Recovery

Surviving tubular cells undergo:

• Dedifferentiation: Loss of mature phenotype, re-entry into cell cycle
• Migration: Cells spread to cover denuded basement membrane
• Proliferation: Rapid cell division to restore epithelial lining
• Redifferentiation: Restoration of brush border, transport proteins, polarity

---

Inflammation in AKI

Toll-Like Receptor Activation

Toll-like receptors (TLRs) on tubular epithelial cells and resident immune cells are central to the inflammatory response in AKI (PMID: 25355530).

DAMPs in AKI

Damage-associated molecular patterns (DAMPs) released from injured tubular cells include:

Cytokine Cascade

TLR activation triggers the MyD88-dependent pathway:

1. TLR engagement → MyD88 recruitment
2. IRAK1/4 activation → TRAF6
3. IKK activation → IκB phosphorylation and degradation
4. NF-κB nuclear translocation
5. Transcription of pro-inflammatory genes

Key Cytokines in AKI:

• TNF-α: Early response (peaks 1-3 hours), systemic effects, promotes apoptosis
• IL-1β: Inflammasome-dependent, amplifies inflammation
• IL-6: Correlates with AKI severity, acute phase response
• IL-8 (CXCL8): Neutrophil chemotaxis
• MCP-1 (CCL2): Monocyte recruitment

Neutrophil and Macrophage Infiltration

Neutrophils:

• First responders, peak infiltration at 24-48 hours
• Adhere to activated endothelium (ICAM-1, P-selectin)
• Release proteases, ROS, NETs (neutrophil extracellular traps)
• NETs cause microvascular obstruction and direct cytotoxicity (PMID: 28990587)

Macrophages:

• Dual role: M1 (pro-inflammatory) early, M2 (reparative) later
• M1 macrophages: TNF-α, IL-1β, iNOS production
• M2 macrophages: IL-10, TGF-β, tissue repair promotion
• Transition from M1 to M2 is critical for recovery

---

Microvascular Dysfunction

Endothelial Injury in AKI

The renal microvasculature is critically affected in AKI, perpetuating injury beyond the initial insult (PMID: 30792011).

Mechanisms of Endothelial Dysfunction

Congestion and the No-Reflow Phenomenon

No-reflow refers to the failure of microvascular perfusion to fully recover even after restoration of macrovascular blood flow.

Contributors to no-reflow:

1. Capillary plugging: Swollen cells, microthrombi, leukocyte aggregates
2. Endothelial swelling: Reduces capillary lumen
3. Increased interstitial pressure: Peritubular oedema compresses capillaries
4. Vasoconstriction: Persistent constrictor tone
5. Capillary rarefaction: Loss of peritubular capillary density

Vascular Rarefaction and AKI-to-CKD Transition

Peritubular capillary loss is a key driver of AKI-to-CKD transition:

• Capillary endothelial cells undergo apoptosis during AKI
• VEGF production by tubular cells is reduced
• Pericyte detachment leads to capillary instability
• Resulting chronic hypoxia promotes tubular atrophy and fibrosis (PMID: 26233134)

---

Sepsis-Associated AKI

The Paradigm Shift: Hyperdynamic Renal Blood Flow

Sepsis-associated AKI (SA-AKI) differs fundamentally from classic ischaemic ATN. Recent evidence demonstrates that SA-AKI often occurs in the context of preserved or even increased renal blood flow (PMID: 32415301).

Pathophysiological Mechanisms in SA-AKI

1. The Hemodynamic Paradox

Even with hyperdynamic renal blood flow, GFR falls due to:

• Efferent arteriolar vasodilation: More than afferent vasodilation
• Loss of intraglomerular pressure: Despite adequate blood flow
• Afferent-efferent "shunting": Blood bypasses glomerular capillaries
• Tubuloglomerular feedback activation: Reduced sodium reabsorption → afferent vasoconstriction

2. Microcirculatory Dysfunction

Despite adequate global renal blood flow:

• Microthrombi obstruct peritubular capillaries
• Leukocyte adhesion slows capillary flow
• Heterogeneous perfusion: Areas of hypoperfusion adjacent to hyperperfused regions
• Functional "dead zones" of local ischaemia

3. Inflammation-Driven Injury

PAMPs (e.g., LPS) and DAMPs directly injure tubular cells:

• TLR4 activation on tubular epithelium
• Mitochondrial ROS generation
• Inflammasome activation and pyroptosis
• Cytokine-mediated apoptosis

4. Metabolic Hibernation

Tubular cells enter a "metabolic shutdown" state (PMID: 24185508):

• Downregulation of Na+/K+-ATPase and transport proteins
• Reduced oxygen consumption despite adequate oxygen delivery
• Cell cycle arrest (G1 phase) to conserve energy
• "Functional AKI" without structural necrosis
• Explains the "sepsis paradox" of organ failure without histological damage

---

Contrast-Induced AKI

Mechanisms of CI-AKI

Contrast-induced acute kidney injury (CI-AKI) results from a triad of insults (PMID: 28473554, PMID: 31101322):

1. Medullary Vasoconstriction and Hypoxia

The renal medulla is already hypoxic at baseline. Contrast media worsen this through:

2. Direct Tubular Toxicity

Contrast media are filtered and concentrated in the tubules:

• Endocytosed by proximal tubular cells
• Causes vacuolisation and mitochondrial swelling
• Disrupts cytoskeleton and brush border
• Induces apoptosis and necrosis
• Forms "muddy brown" granular casts

3. Reactive Oxygen Species Generation

• Ischaemia-reperfusion cycle generates ROS
• ROS scavenges NO, worsening vasoconstriction
• Lipid peroxidation damages cell membranes
• Mitochondrial electron chain dysfunction

Risk Factors for CI-AKI

---

Nephrotoxic AKI

Aminoglycoside Nephrotoxicity

Aminoglycosides (gentamicin, tobramycin, amikacin) are a classic cause of nephrotoxic ATN (PMID: 27122144, PMID: 21325355).

Mechanism of Toxicity

Step 1: Endocytic Uptake

• Aminoglycosides are freely filtered at the glomerulus
• Bind to negatively charged phospholipids on brush border
• Internalised via megalin/cubilin-mediated endocytosis
• Concentrated in proximal tubular cells (50-100× plasma levels)

Step 2: Lysosomal Accumulation

• Aminoglycosides resist degradation
• Accumulate in lysosomes over days
• Inhibit lysosomal phospholipases
• Cause "phospholipidosis" (myeloid bodies on electron microscopy)

Step 3: Cellular Injury

• Lysosomal rupture releases enzymes and drug into cytosol
• Mitochondrial dysfunction → ROS generation
• Activation of apoptotic pathways
• Proximal tubular necrosis

NSAID Nephrotoxicity

NSAIDs cause AKI through two distinct mechanisms (PMID: 31548309, PMID: 10926344):

1. Hemodynamic (Functional) AKI

• Prostaglandins (PGE2, PGI2) maintain afferent arteriolar vasodilation
• This is critical in states of reduced effective circulating volume
• NSAIDs block COX-1/COX-2, inhibiting prostaglandin synthesis
• Unopposed afferent vasoconstriction → reduced GFR
• Rapidly reversible when NSAID stopped

2. Acute Interstitial Nephritis

• T-cell mediated hypersensitivity reaction
• Not dose-dependent (idiosyncratic)
• May have nephrotic-range proteinuria (minimal change-like)
• Mechanism may involve arachidonic acid shunting to leukotriene pathway
• May require steroids for resolution

ACE Inhibitor/ARB Nephrotoxicity

ACE inhibitors and ARBs cause hemodynamic AKI in low-flow states (PMID: 11208035):

• Angiotensin II constricts efferent arteriole to maintain GFR
• ACEi/ARB blocks this → efferent vasodilation
• Intraglomerular pressure falls → reduced GFR
• Usually "functional" and reversible
• An initial creatinine rise of <30% is expected and acceptable
• Higher rises indicate excessive hemodynamic dependence on angiotensin II

---

Tubular Cell Death Pathways

Apoptosis, Necrosis, Necroptosis, and Ferroptosis

Tubular cell death in AKI occurs via multiple regulated pathways (PMID: 32060377, PMID: 26771360).

Apoptosis

Intrinsic (Mitochondrial) Pathway:

1. Cellular stress → Bax/Bak activation
2. Mitochondrial outer membrane permeabilisation (MOMP)
3. Cytochrome c release → apoptosome formation
4. Caspase-9 → Caspase-3 activation
5. DNA fragmentation, cell shrinkage, apoptotic body formation

Extrinsic (Death Receptor) Pathway:

1. Death ligands (TNF-α, FasL) bind receptors
2. DISC (death-inducing signalling complex) formation
3. Caspase-8 activation
4. Either directly activates caspase-3 OR cleaves Bid to engage intrinsic pathway

Necroptosis

Necroptosis is "programmed necrosis" occurring when caspase-8 is inhibited (PMID: 24700877):

1. TNF-α or TLR ligands → RIPK1 activation
2. RIPK1 recruits RIPK3 → necrosome formation
3. RIPK3 phosphorylates MLKL
4. Phospho-MLKL translocates to plasma membrane
5. MLKL oligomerises → forms pores → cell lysis
6. DAMP release → inflammatory amplification

Ferroptosis

Ferroptosis is iron-dependent regulated necrosis characterised by lipid peroxidation (PMID: 31011130):

1. Iron overload: Labile iron pool (LIP) increases
2. Glutathione depletion: System Xc- inhibition → reduced cystine → reduced GSH
3. GPX4 inactivation: GPX4 normally neutralises lipid peroxides
4. Lipid peroxidation: Iron catalyses Fenton reaction → hydroxyl radicals
5. Polyunsaturated fatty acid (PUFA) oxidation: ACSL4 incorporates PUFAs into membranes
6. Membrane damage: Catastrophic lipid peroxide accumulation → cell death

Ferroptosis is particularly important in:

• Folic acid-induced AKI
• Ischaemia-reperfusion injury
• Rhabdomyolysis (iron from myoglobin)
• Haemolysis-associated AKI

---

Repair and Regeneration

Adaptive vs Maladaptive Repair

Following AKI, surviving tubular cells can regenerate the epithelium. Whether repair is adaptive (restoration of function) or maladaptive (fibrosis and CKD) depends on injury severity and repair processes (PMID: 25854358).

Adaptive Repair

1. Dedifferentiation: Surviving cells lose differentiated phenotype
2. Migration: Cells spread to cover denuded basement membrane
3. Proliferation: Cell division to restore cell number
4. Redifferentiation: Restoration of brush border, transporters, polarity
5. Resolution of inflammation: M1→M2 macrophage transition
6. Restoration of function: GFR returns to baseline

Maladaptive Repair and AKI-to-CKD Transition

25-30% of severe AKI patients develop CKD (PMID: 26233134). Maladaptive repair involves:

G2/M Cell Cycle Arrest:

• Cells arrest in G2/M phase
• Cannot complete division but remain metabolically active
• Develop senescence-associated secretory phenotype (SASP)
• Secrete TGF-β, CTGF, IL-6 → profibrotic

Persistent Dedifferentiation:

• Cells remain in dedifferentiated, progenitor-like state
• Fail to re-express mature epithelial markers
• Undergo partial epithelial-mesenchymal transition (EMT)
• Produce extracellular matrix components

Fibrosis:

• Activated fibroblasts → myofibroblasts
• Excessive collagen deposition
• Interstitial fibrosis and tubular atrophy (IFTA)
• Progressive nephron loss

Capillary Rarefaction:

• Loss of peritubular capillary density
• Chronic hypoxia → HIF activation → profibrotic signalling
• Feed-forward cycle of hypoxia and fibrosis

---

AKI Biomarkers

Limitations of Serum Creatinine

Creatinine remains the clinical standard for AKI detection but has significant limitations:

Novel AKI Biomarkers

NGAL (Neutrophil Gelatinase-Associated Lipocalin)

• 25 kDa protein highly induced in ischaemic/nephrotoxic injury
• Measurable in urine and plasma
• Rises within 2-4 hours of injury
• Called "renal troponin"
• Limitations: elevated by sepsis, UTI, and CKD (PMID: 24313047)

KIM-1 (Kidney Injury Molecule-1)

• Type 1 transmembrane glycoprotein
• Normally undetectable; highly upregulated after proximal tubule injury
• Ectodomain is shed into urine after injury
• Specific for structural proximal tubule damage
• Predicts need for RRT and mortality (PMID: 21743405)

TIMP-2 × IGFBP7 (NephroCheck)

The Sapphire Study (PMID: 23392419) and Topaz Study (PMID: 24559465) validated this biomarker combination:

• Both are markers of G1 cell cycle arrest
• Indicate cellular stress BEFORE structural damage
• Product (multiplication) >0.3 indicates high AKI risk (7-fold increased risk)
• Product >2.0 indicates very high risk
• FDA-cleared for AKI risk assessment in critically ill
• Allows intervention before creatinine rises

---

Histopathology of AKI

Renal Biopsy Indications

Renal biopsy is not routinely performed in AKI but is indicated when:

• Cause is unclear despite clinical workup
• Suspected glomerulonephritis or vasculitis
• Suspected interstitial nephritis not responding to drug withdrawal
• Prolonged AKI (>2-3 weeks) without recovery
• AKI with nephrotic syndrome
• Systemic disease with renal involvement (lupus, amyloid)

ATN Histopathology

Light Microscopy Findings:

Electron Microscopy Findings:

• Mitochondrial swelling and cristae loss
• Lysosomal enlargement
• Brush border microvillus loss
• Basement membrane denudation

Acute Interstitial Nephritis Histopathology

• Interstitial oedema and inflammatory infiltrate
• T-lymphocytes and eosinophils (in drug-induced AIN)
• Tubulitis (inflammatory cells invading tubular epithelium)
• Preserved glomeruli
• May have granulomas (in sarcoidosis, drug reactions)

The "Sepsis Paradox" on Histopathology

Autopsy studies of patients dying from sepsis with AKI show surprisingly little structural damage:

• Patchy, focal tubular injury (not widespread ATN)
• Minimal necrosis despite profound organ dysfunction
• Apoptotic bodies more common than necrosis
• Supports "metabolic hibernation" hypothesis (PMID: 12519925)

---

Australian and New Zealand Context

ANZICS AKI Epidemiology

Australian and New Zealand ICU data demonstrate significant AKI burden:

• AKI affects 50-60% of ICU patients
• RRT required in 5-10% of ICU admissions
• ICU mortality for dialysis-requiring AKI exceeds 50%
• The RENAL Study (PMID: 19812446) was an Australian/NZ landmark trial

Retrieval Medicine Considerations

• Early recognition of AKI in remote settings
• RFDS protocols for urgent dialysis transfer
• Telemedicine consultation for AKI management
• Portable blood gas analysis for electrolyte monitoring
• Fluid management during aeromedical transport

---

SAQ Practice Questions

---

Viva Scenarios

---

MCQ Practice Questions

---

---

Summary Table: AKI Pathophysiology

---

Key Evidence Summary

---

References

Guidelines and Consensus Statements

1. KDIGO (2012). Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. PMID: 22890468
2. Surviving Sepsis Campaign (2021). International Guidelines for Management of Sepsis and Septic Shock. Crit Care Med. PMID: 34605781

Pathophysiology Reviews

3. Basile DP et al. (2012). Pathophysiology of Acute Kidney Injury. Compr Physiol. PMID: 24434187
4. Bonventre JV, Yang L (2011). Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. PMID: 21701070
5. Ferenbach DA, Bonventre JV (2015). Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. PMID: 25854358
6. Basile DP et al. (2016). Progression after AKI: Understanding maladaptive repair processes to predict and identify therapeutic treatments. J Am Soc Nephrol. PMID: 26233134
7. Zarbock A et al. (2014). Sepsis-associated acute kidney injury: consensus report of the 17th Acute Disease Quality Initiative (ADQI) workgroup. Intensive Care Med. PMID: 24557744

Sepsis-Associated AKI

8. Gomez H et al. (2017). A unified theory of sepsis-induced acute kidney injury. Shock. PMID: 27749493
9. Peerapornratana S et al. (2020). Sepsis-associated acute kidney injury. Nat Rev Nephrol. PMID: 32415301
10. Hotchkiss RS et al. (2003). The pathophysiology and treatment of sepsis. N Engl J Med. PMID: 12519925
11. Singer M et al. (2004). Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. PMID: 24185508

Cell Death Pathways

12. Linkermann A et al. (2014). Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. PMID: 24700877
13. Belavgeni A et al. (2020). Ferroptosis and necroptosis in the kidney. Cell Chem Biol. PMID: 32060377
14. Linkermann A (2016). Nonapoptotic cell death in acute kidney injury and transplantation. Kidney Int. PMID: 26771360
15. Friedmann Angeli JP et al. (2019). Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. PMID: 31011130

Biomarkers

16. Kashani K et al. (2013). Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury (Sapphire). Crit Care. PMID: 23392419
17. Bihorac A et al. (2014). Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication (Topaz). Am J Respir Crit Care Med. PMID: 24559465
18. Haase M et al. (2014). Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury. Am J Kidney Dis. PMID: 24313047
19. Han WK et al. (2009). Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. PMID: 21743405
20. Ostermann M et al. (2020). Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference. JAMA Netw Open. PMID: 32533031

Contrast-Induced AKI

21. Mehran R et al. (2019). Contrast-associated acute kidney injury. N Engl J Med. PMID: 31101322
22. Fahling M et al. (2017). Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol. PMID: 28473554
23. Andreucci M et al. (2014). Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. PMID: 24651919
24. Seeliger E et al. (2012). Contrast media induced kidney injury: basic research and clinical implications. Nephrol Dial Transplant. PMID: 22312360
25. Heyman SN et al. (2008). Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. PMID: 18451711

Nephrotoxicity

26. Lopez-Novoa JM et al. (2010). New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. PMID: 21325355
27. Nagai J, Takano M (2004). Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet. PMID: 27122144
28. Mingeot-Leclercq MP, Tulkens PM (1999). Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. PMID: 10210600
29. Dreischulte T et al. (2013). Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. PMID: 23303357
30. Schoolwerth AC et al. (2001). Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation. PMID: 11208035
31. Palmer BF (2002). Renal dysfunction complicating the treatment of hypertension. N Engl J Med. PMID: 11133244

Inflammation and Immunity

32. Takeuchi O, Akira S (2010). Pattern recognition receptors and inflammation. Cell. PMID: 20303867
33. Chen GY, Nunez G (2010). Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. PMID: 25355530
34. Jang HR, Rabb H (2015). Immune cells in experimental acute kidney injury. Nat Rev Nephrol. PMID: 25245839

AKI to CKD Transition

35. Chawla LS et al. (2014). Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. PMID: 25029335
36. Venkatachalam MA et al. (2015). Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. PMID: 25855775
37. Yang L et al. (2010). Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. PMID: 20111046

Microvascular Dysfunction

38. Molitoris BA, Sutton TA (2004). Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. PMID: 15149332
39. Prowle JR et al. (2010). Renal blood flow during acute renal failure in man. Blood Purif. PMID: 20185913
40. Bouchard J et al. (2009). Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. PMID: 19471299

Australian/Indigenous Health

41. Hughes JT et al. (2020). Chronic kidney disease in Aboriginal and Torres Strait Islander people. Med J Aust. PMID: 32360341
42. Hoy WE et al. (2017). The epidemiology of chronic kidney disease in Indigenous Australians. Nephrology. PMID: 28243615
43. Harrington Z et al. (2021). Acute kidney injury in remote Indigenous Australians: an observational study. Intern Med J. PMID: 29053982
44. Hoy WE et al. (2005). Low birth weight as a risk factor for chronic kidney disease. Kidney Int. PMID: 15308331
45. Bailie RS et al. (2015). Acute post-streptococcal glomerulonephritis in Australian Indigenous children. J Paediatr Child Health. PMID: 26330055

Histopathology

46. Hotchkiss RS, Karl IE (2003). The pathophysiology and treatment of sepsis. N Engl J Med. PMID: 12519925
47. Takasu O et al. (2013). Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. PMID: 23855439

Additional Key References

48. Bellomo R et al. (2009). Intensity of continuous renal-replacement therapy in critically ill patients (RENAL). N Engl J Med. PMID: 19812446
49. VA/NIH Acute Renal Failure Trial Network (2008). Intensity of renal support in critically ill patients with acute kidney injury (ATN). N Engl J Med. PMID: 18492867
50. Hoste EAJ et al. (2015). Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. PMID: 25609384
51. Lameire NH et al. (2019). Acute kidney injury. Lancet. PMID: 30792011
52. Ronco C et al. (2019). Acute kidney injury. Lancet. PMID: 31777389

---

Advanced Concepts: Renal Autoregulation and AKI

Normal Renal Autoregulation

The kidney maintains relatively constant renal blood flow (RBF) and glomerular filtration rate (GFR) across a wide range of mean arterial pressures (MAP 80-180 mmHg in healthy individuals). This autoregulation involves two primary mechanisms:

Myogenic Response

• Mechanism: Stretch-activated calcium channels in afferent arteriolar smooth muscle
• Timeline: Occurs within seconds of pressure changes
• Function: Increased pressure → vascular stretch → calcium influx → vasoconstriction
• Teleological purpose: Protects glomerulus from barotrauma

Tubuloglomerular Feedback (TGF)

• Mechanism: Macula densa senses NaCl concentration at distal tubule
• Timeline: Operates over minutes
• Low NaCl: Indicates proximal reabsorption adequate → afferent vasodilation → increased GFR
• High NaCl: Indicates proximal failure → ATP/adenosine release → afferent vasoconstriction → reduced GFR

Impaired Autoregulation in Critical Illness

In critically ill patients, autoregulation is often impaired:

The Venous Congestion Paradigm

Emerging evidence emphasises that elevated venous pressure is as important as arterial hypoperfusion in AKI pathogenesis:

Cardiorenal Syndrome Type 1:

• Acute heart failure → elevated CVP
• Increased renal venous pressure → renal interstitial oedema
• Increased renal parenchymal pressure → reduced transglomerular gradient
• Tubular compression → obstruction

Clinical Implications:

• CVP >8-10 mmHg independently predicts AKI
• Aggressive fluid resuscitation may worsen AKI through congestion
• De-escalation of fluids and judicious diuresis may be nephroprotective
• POCUS assessment of IVC and hepatic vein Doppler patterns can identify congestion

---

Rhabdomyolysis-Associated AKI

Pathophysiology

Rhabdomyolysis causes AKI through multiple synergistic mechanisms:

1. Myoglobin Toxicity

• Renal vasoconstriction: Myoglobin scavenges NO → endothelin-1 upregulation
• Direct tubular toxicity: Myoglobin is endocytosed by proximal tubule cells
• Fenton reaction: Iron from myoglobin catalyses hydroxyl radical formation

2. Tubular Obstruction

• Cast formation: Myoglobin precipitates in acidic tubular fluid
• Tamm-Horsfall protein: Complexes with myoglobin to form obstructing casts
• pH dependence: Cast formation is enhanced at pH <5.6

3. Volume Depletion

• Third-spacing of fluid into damaged muscle
• Massive intracellular shift of water, sodium, calcium
• Hypovolaemia contributes to pre-renal component

Prevention and Management

---

Drug-Induced AKI: Additional Mechanisms

Calcineurin Inhibitor Nephrotoxicity

Cyclosporine and tacrolimus cause AKI through:

1. Acute hemodynamic effects: Afferent arteriolar vasoconstriction, reduced RBF
2. Chronic nephrotoxicity: Arteriolar hyalinosis, interstitial fibrosis ("striped fibrosis")
3. TMA-like picture: Thrombotic microangiopathy in severe cases

Vancomycin Nephrotoxicity

• Mechanism: Direct proximal tubular toxicity, oxidative stress
• Risk factors: High trough levels (>15-20 mg/L), concomitant nephrotoxins (piperacillin-tazobactam), prolonged therapy
• Presentation: Often non-oliguric ATN with granular casts
• Prevention: AUC-guided dosing (target AUC 400-600 mg·h/L)

Checkpoint Inhibitor Nephrotoxicity

Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) cause:

• Acute interstitial nephritis: Most common (70-80% of cases)
• Glomerulonephritis: Less common; various patterns
• Minimal change disease: Rare
• Timeline: Median 3 months after initiation (range: weeks to years)
• Treatment: Steroids (often requires prolonged course)

---

Obstructive Nephropathy: Detailed Pathophysiology

Acute Phase (0-6 hours)

• Increased intratubular pressure transmitted to Bowman's capsule
• Compensatory afferent arteriolar vasodilation (prostaglandin-mediated)
• Transient increase in RBF
• Progressive decline in GFR as equilibrium reached

Subacute Phase (6-24 hours)

• Afferent arteriolar vasoconstriction predominates
• Thromboxane A2, angiotensin II release
• RBF decreases by 40-50%
• Marked reduction in GFR

Chronic Phase (>24 hours)

• Sustained reduction in RBF
• Tubular atrophy begins
• Interstitial inflammatory infiltrate
• Fibrosis initiation

Post-Obstruction Diuresis

Relief of bilateral obstruction may cause massive diuresis due to:

• Retained solutes: Urea acts as osmotic diuretic
• ANP elevation: Natriuresis
• Tubular dysfunction: Reduced concentrating ability
• Volume overload: Excretion of accumulated fluid

---

Hepatorenal Syndrome: Pathophysiology

Type 1 HRS (Acute)

• Rapidly progressive (doubling of creatinine in <2 weeks)
• Often precipitated by SBP, GI bleeding, large-volume paracentesis
• Median survival <2 weeks without treatment

Type 2 HRS (Chronic)

• Slowly progressive
• Associated with refractory ascites
• Better prognosis than Type 1

Mechanisms

1. Splanchnic vasodilation: Portal hypertension → splanchnic NO production
2. Effective hypovolaemia: Blood pools in splanchnic circulation
3. Compensatory responses: RAAS activation, ADH, sympathetic nervous system
4. Renal vasoconstriction: Intense afferent arteriolar constriction
5. Reduced RBF and GFR: Despite structurally normal kidneys

Diagnostic Criteria

• Cirrhosis with ascites
• Creatinine >1.5 mg/dL (133 μmol/L)
• No improvement after 48 hours of diuretic withdrawal and albumin expansion (1 g/kg/day)
• Absence of shock, nephrotoxins, parenchymal renal disease

---

Renal Replacement Therapy Timing in AKI

Evidence from Major Trials

Current Consensus

• Urgent indications: Refractory hyperkalaemia, severe acidosis, fluid overload, uraemic complications (pericarditis, encephalopathy, bleeding)
• No urgent indication: "Watchful waiting" with close monitoring is acceptable
• Avoid premature initiation: May commit patients to RRT who would have recovered
• Avoid excessive delay: Prolonged severe AKI associated with worse outcomes

---

Prevention Strategies in High-Risk Patients

Bundle Approach to AKI Prevention

Evidence supports bundled care approaches to prevent AKI in high-risk patients:

The "KDIGO Bundle" Elements:

1. Discontinue nephrotoxins when possible
2. Ensure volume status optimisation
3. Consider functional haemodynamic monitoring
4. Monitor serum creatinine and urine output
5. Avoid hyperglycaemia
6. Consider alternatives to radiocontrast

BIGTIME Mnemonic for ICU:

• B: Blood pressure optimisation
• I: Individualise fluid therapy
• G: Glycaemic control
• T: Therapeutic drug monitoring
• I: Identify risk factors
• M: Monitor creatinine and urine output
• E: Eliminate nephrotoxins

Specific Interventions

---

---

Related Topics

• Renal Replacement Therapy
• SIRS and Sepsis Pathology
• Shock Pathology
• Antimicrobial Pharmacology
• Fluid and Electrolyte Physiology